

MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

IRVINE, CA, and HERSTAL, BELGIUM – 07:00 CET, April 4, 2017 – MDxHealth SA (Euronext: MDXH.BR), today announced that it has signed an exclusive licensing deal with Ghent University in Belgium for its proprietary molecular diagnostic visualization technology that will allow the visual detection of epigenetic changes associated with cancer in both tissue and liquid specimens. In a separate agreement, MDxHealth has also joined forces with the University to leverage the licensed technology for the Company's current and future in vitro diagnostic (IVD) kits and laboratory developed tests (LDTs).

Under the terms of the license agreement, MDxHealth has exclusive use of Ghent University's diagnostic visualization technology for urological cancers. Together, through their expanded research collaboration, MDxHealth and Ghent University scientists will initially focus on validating cancer-specific biomarkers for prostate and bladder cancer.

"We are very excited to continue our long-standing and collaborative relationship with Ghent University," **said Dr. Jan Groen, CEO of MDxHealth**. "The exclusively licensed technology and R&D collaboration has the potential to significantly enhance our current tests and ultimately provide a platform to expand into other difficult to diagnose cancers in the future."

The ground-breaking, diagnostic technology invented at Ghent University employs biomarker-specific probes in a methylation in situ hybridization (MISH) platform to directly target and visualize methylation changes associated with cancer in a patient's DNA. The MISH platform uses chromogens and fluorescent dyes that make the targeted biomarkers glow in a different color if they are methylated. This is the first time, methylation patterns can be visualized at a molecular level within a histological context.

"It is our privilege to join efforts with MDxHealth, pioneer in epigenetic biomarker assay development, to implement this exciting new technology." **said Prof. Davy Vanden Broeck, Department of Uro-gynaecology at Ghent University**.

About Ghent University

Ghent University is a 200-year-old public research university located in Ghent, Belgium. It is recognized as a top-ranked university within Belgium and globally. In addition to academic programs, the University, facilitated by industrial research funded business units such as BIOMARKED (<http://www.ugent.be/en/industry>), works closely with industry through business development programs, start-up incubators and collaboration opportunities such as the Center of Excellence in Pharmaco(epi)genomics jointly founded by Ghent University and MDxHealth to bring together researchers in bioinformatics and genomic and methylome sequencing. More information about Ghent University is available at <https://www.ugent.be/en>.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information:

Shalon Roth, EVP Corporate Communications
MDxHealth
UK: +44 (0)7393 906278
@ShalonRoth
info@mdxhealth.com

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.